Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tiziana Life Sciences Ltd
(NQ:
TLSA
)
1.230
+0.010 (+0.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tiziana Life Sciences Ltd
< Previous
1
2
3
4
5
6
7
8
Next >
Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update
October 05, 2023
--News Direct--
Via
News Direct
Cathie Wood Sells $25 Million In Tesla Stock As TSLA Flashes Aggressive Buy Signal
October 05, 2023
Wood's Ark Invest unloaded nearly 100,000 TSLA shares Wednesday.
Via
Investor's Business Daily
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
October 04, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c
Via
Benzinga
Latest AI Quantum Computing News And Company Stock Performances YTD
October 03, 2023
The global quantum computing market is expected to grow at a CAGR of 38.3% over the next 5 years which presents an incredible opportunity for investors so which AI quantum computing stocks are...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients
September 27, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) has taken a major step towards addressing Secondary Progressive Multiple Sclerosis (SPMS) by initiating Phase 2a clinical trials for its intranasal foralumab...
Via
Benzinga
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
September 26, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Cathie Wood Dumps 170,000 Tesla Shares This Week As TSLA Falls Harder Than The S&P 500
September 22, 2023
Wood continued selling Tesla shares as TSLA forged a new buy point.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Tesla Cybertruck To Be Used For Oracle's Next-Gen Police Car
September 20, 2023
Oracle Corp (NYSE: ORCL) co-founder and Executive Chairman Larry Ellison recently made a surprising reveal during his CloudWorld talk.
Via
Benzinga
Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light
September 12, 2023
Tiziana Life Sciences Ltd.
Via
Benzinga
Exposures
Product Safety
Tiziana Life Sciences' Alzheimer's treatment validated in new study
September 12, 2023
--News Direct--
Via
News Direct
Tiziana Life Sciences' Alzheimer's treatment validated in new study
September 12, 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company...
Via
TheNewswire.com
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...
Via
Benzinga
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
September 06, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
August 23, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
August 23, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
August 17, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision
August 16, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced...
Via
Benzinga
Exposures
Product Safety
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 15, 2023
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 15, 2023
Via
Benzinga
Why Tiziana Life Sciences Stock (TLSA) Is Climbing
August 15, 2023
Tiziana Life Sciences, Ltd (NASDAQ: TLSA) shares are trading higher Tuesday after the company announced that the FDA has cleared the Investigational New Drug (IND) application for intranasal foralumab...
Via
Benzinga
Exposures
Product Safety
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
August 15, 2023
--News Direct--
Via
News Direct
Exposures
Product Safety
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
August 15, 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after announcing that Tiziana has received FDA clearance...
Via
TheNewswire.com
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 15, 2023
Via
Benzinga
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
August 15, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
August 09, 2023
--News Direct--
Via
News Direct
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
August 08, 2023
Tiziana Life Sciences, Inc.
Via
Benzinga
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
August 04, 2023
--News Direct--
Via
News Direct
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
August 03, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 01, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.